Category: Press Release

2021.12.31

I-Mab Announces Upcoming Participation at January Conferences

2021.12.27

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

2021.12.20

I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization

2021.12.15

I-Mab Receives IND Approval for Phase 1 Clinical Trial of Bispecific Antibody TJ-CD4B in Solid Tumors in China

2021.12.14

I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021

2021.12.08

I-Mab Announces First Patient Dosed in U.S. Phase 1 Study of Protollin for the Treatment of Alzheimer’s Disease

2021.12.07

I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited

2021.12.03

I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors

2021.11.10

I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa

2021.11.09

I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC